Inhibitors of NF-κB signaling:: 785 and counting

被引:495
作者
Gilmore, T. D. [1 ]
Herscovitch, M. [1 ]
机构
[1] Boston Univ, Dept Biol, Boston, MA 02215 USA
基金
美国国家卫生研究院; 加拿大自然科学与工程研究理事会;
关键词
NF-kappa B; IKK; signal transduction; inhibition; inflammation; cancer therapy;
D O I
10.1038/sj.onc.1209982
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nuclear factor kappa B (NF-kappa B) transcription factors regulate several important physiological processes, including inflammation and immune responses, cell growth, apoptosis, and the expression of certain viral genes. Therefore, the NF-kappa B signaling pathway has also provided a focus for pharmacological intervention, primarily in situations of chronic inflammation or in cancer, where the pathway is often constitutively active and plays a key role in the disease. Now that many of the molecular details of the NF-kappa B pathway are known, it is clear that modulators of this pathway can act at several levels. As described herein, over 750 inhibitors of the NF-kappa B pathway have been identified, including a variety of natural and synthetic molecules. These compounds include antioxidants, peptides, small RNA/DNA, microbial and viral proteins, small molecules, and engineered dominant-negative or constitutively active polypeptides. Several of these molecules act as general inhibitors of NF-kappa B induction, whereas others inhibit specific pathways of induction. In addition, some compounds appear to target multiple steps in the NF-kappa B pathway. Compounds designed as specific NF-kappa B inhibitors are not yet in clinical use, but they are likely to be developed as treatments for certain cancers and neurodegenerative and inflammatory diseases. Moreover, the therapeutic and preventative effects of many natural products may, at least in part, be due to their ability to inhibit NF-kappa B.
引用
收藏
页码:6887 / 6899
页数:13
相关论文
共 172 条
[1]   Oral administration of the anti-inflammatory substance triflusal results in the downregulation of constitutive transcription factor NF-κB in the postnatal rat brain [J].
Acarin, L ;
González, B ;
Castellano, B .
NEUROSCIENCE LETTERS, 2000, 288 (01) :41-44
[2]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[3]  
AGGARWAL BB, 2006, IN PRESS BIOCH PHARM
[4]   Inhibition of NF-κB activation by peptides targeting NF-κB essential modulator (NEMO) oligomerization [J].
Agou, F ;
Courtois, G ;
Chiaravalli, J ;
Baleux, F ;
Coïc, YM ;
Traincard, F ;
Israël, A ;
Véron, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (52) :54248-54257
[5]   Recruitment of IκBα to the hes1 promoter is associated with transcriptional repression [J].
Aguilera, C ;
Hoya-Arias, R ;
Haegeman, G ;
Espinosa, L ;
Bigas, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (47) :16537-16542
[6]   Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of surgical ischemic acute renal failure [J].
Aravindan, N ;
Natarajan, M ;
Shaw, AD .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2006, 20 (02) :179-186
[7]   HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation [J].
Azuma, RW ;
Suzuki, J ;
Ogawa, M ;
Futamatsu, H ;
Koga, N ;
Onai, Y ;
Kosuge, H ;
Isobe, M .
CARDIOVASCULAR RESEARCH, 2004, 64 (03) :412-420
[8]   The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation [J].
Bales, KR ;
Du, YS ;
Dodel, RC ;
Yan, GM ;
Hamilton-Byrd, E ;
Paul, SM .
MOLECULAR BRAIN RESEARCH, 1998, 57 (01) :63-72
[9]   Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression [J].
Basseres, D. S. ;
Baldwin, A. S. .
ONCOGENE, 2006, 25 (51) :6817-6830
[10]  
Bentires-Alj M, 1999, CANCER RES, V59, P811